Molecular imaging using PET for breast cancer.
Molecular imaging can visualize the biological processes at the molecular and cellular levels in vivo using certain tracers for specific molecular targets. Molecular imaging of breast cancer can be performed with various imaging modalities, however, positron emission tomography (PET) is a sensitive and non-invasive molecular imaging technology and this review will focus on PET molecular imaging of breast cancer, such as FDG-PET, FLT-PET, hormone receptor PET, and anti-HER2 PET.
Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. hikuriha@ncc.go.jp.
Hiroaki
H
Kurihara
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Chikako
C
Shimizu
Department of Neurosurgery, National Cancer Center Hospital, Tokyo, Japan.
Yasuji
Y
Miyakita
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Masayuki
M
Yoshida
Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan.
Akinobu
A
Hamada
RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan.
Yousuke
Y
Kanayama
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kan
K
Yonemori
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jun
J
Hashimoto
Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hitomi
H
Tani
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Makoto
M
Kodaira
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Mayu
M
Yunokawa
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Harukaze
H
Yamamoto
RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan.
Yasuyoshi
Y
Watanabe
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yasuhiro
Y
Fujiwara
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kenji
K
Tamura
D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging* / Q000378:metabolism; D000068818:Cetuximab; D015224:Dideoxynucleosides; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D057054:Molecular Imaging / Q000379:methods*; D009653:Norprogesterones; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D000068878:Trastuzumab
D000068258:Bevacizumab; D000068818:Cetuximab; D015224:Dideoxynucleosides; D066246:ErbB Receptors; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D009653:Norprogesterones; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; D017526:Receptor, IGF Type 1; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D040262:Receptors, Vascular Endothelial Growth Factor; D000068878:Trastuzumab; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C002854:alovudine
Breast cancer; HER2; Molecular imaging; Molecular target therapy; PET